ImmunityBio (IBRX) Stock Price, News & Analysis

Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Key Stats

• Today's Range: $2.23 to $2.35
• 50-Day Range: $2.24 to $3.13
• 52-Week Range: $1.83 to $7.48
• Volume: 9.52 million shs
• Average Volume: 9.55 million shs
• Market Capitalization: $2.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.75
• Consensus Rating: Buy

ImmunityBio Stock Analysis - MarketRank™

ImmunityBio scored higher than 50% of companies evaluated by MarketBeat, and ranked 556th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ImmunityBio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ImmunityBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunityBio are expected to grow in the coming year, from ($0.92) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunityBio is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunityBio is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.13% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in ImmunityBio has recently increased by 0.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunityBio does not currently pay a dividend.

Dividend Growth

ImmunityBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

35.13% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in ImmunityBio has recently increased by 0.12%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.73

News Sentiment

ImmunityBio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ImmunityBio this week, compared to 4 articles on an average week.

Search Interest

24 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

11 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunityBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

76.79% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.58% of the stock of ImmunityBio is held by institutions.

IBRX Stock Analysis - Frequently Asked Questions

How have IBRX shares performed this year?

ImmunityBio's stock was trading at $2.56 at the beginning of the year. Since then, IBRX stock has decreased by 9.8% and is now trading at $2.31.

How were ImmunityBio's earnings last quarter?

ImmunityBio, Inc. (NASDAQ:IBRX) issued its earnings results on Tuesday, August, 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). The firm earned $26.43 million during the quarter, compared to analyst estimates of $21.95 million.

Who are ImmunityBio's major shareholders?

ImmunityBio's top institutional investors include Armistice Capital LLC (0.82%), Geode Capital Management LLC (0.65%), AlphaCore Capital LLC (0.31%) and JPMorgan Chase & Co. (0.11%). Insiders that own company stock include Michael D Blaszyk and John Owen Brennan.
View institutional ownership trends.

How do I buy shares of ImmunityBio?

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmunityBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunityBio investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Home Depot (HD), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IBRX
• CIK: 1326110
• Web: immunitybio.com
• Phone: (858) 633-0300
• Fax: N/A
• Employees: 590
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ImmunityBio: $10.75
• High Price Target: $24.00
• Low Price Target: $5.00
• Potential Upside/Downside: +365.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$413.56 million
• Net Margins: -648.57%
• Pretax Margin: -648.65%
• Return on Equity: N/A
• Return on Assets: -113.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.11
• Quick Ratio: 3.98

Sales & Book Value

• Annual Sales: $14.74 million
• Price / Sales: 148.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.60) per share
• Price / Book: -3.85

Miscellaneous

• Outstanding Shares: 945,260,000
• Free Float: 219,394,000
• Market Cap: $2.18 billion
• Optionable: Optionable
• Beta: 0.12